Theravance Biopharma, Inc. (TBPH) Institutional Ownership

Ownership Summary

Theravance Biopharma, Inc. (NASDAQ:TBPH) has 166 institutional investors with active 13F positions as of December 2025.

• These investors held 95.5% of outstanding shares in December 2025, up from 94.8% in September 2025.
• Their total shares held in TBPH increased 2.17% from the prior quarter, while the number of investors in Theravance Biopharma increased 30.71% year over year.
• Activity in TBPH broke down as 95 buyers, 47 sellers, and 24 unchanged among 166 total holders.
• The aggregate institutional position in Theravance Biopharma amounted to 49.56Mn shares as of December 2025, up by 1.05Mn shares quarter on quarter, and up 4.13Mn shares year over year.
• Madison Avenue Partners, LP holds the largest position in TBPH at 9.51Mn shares as of December 31, 2025, or 18.32% of shares outstanding.
• The biggest buyers of Theravance Biopharma for the quarter ending December 2025 included VANGUARD CAPITAL MANAGEMENT LLC (1.78Mn), TWO SIGMA INVESTMENTS, LP (721.16K), Newtyn Management, LLC (541.63K), VANGUARD PORTFOLIO MANAGEMENT LLC (400.76K), Janus Henderson Group Plc (357.46K).
• The biggest sellers of Theravance Biopharma for the quarter ending December 2025 included ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (635.71K), D. E. Shaw & Co., Inc. (305.9K), Morgan Stanley (292.85K), Jpmorgan Chase & Co (289.14K), MARSHALL WACE, LLP (259.73K).
• Per Business Quant data, the top 10 holders of Theravance Biopharma for the quarter ending December 2025 are Madison Avenue Partners, LP (9.51Mn), Weiss Asset Management LP (7.46Mn), Newtyn Management, LLC (4.84Mn), BlackRock, Inc. (4.3Mn), Irenic Capital Management LP (2.76Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.78Mn), State Street Corp (1.3Mn), ACADIAN ASSET MANAGEMENT LLC (1.28Mn), TWO SIGMA INVESTMENTS, LP (1.26Mn), GEODE CAPITAL MANAGEMENT, LLC (1.14Mn).